Levact

Bendamustine Hydrochloride, the active ingredient in Levact, is an alkylating agent (nitrogen mustard) presented as an injection solution for intravenous use. It is employed in the treatment of chronic lymphocytic leukemia and non‑Hodgkin lymphoma in adult patients and is indicated for those who have not responded adequately to prior therapies.

GNH USA supplies Levact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality and regulatory compliance across global markets throughout Europe.

Bendamustine Hydrochloride is an alkylating antineoplastic agent used in hematologic malignancies.

- Chronic lymphocytic leukemia (CLL): improves remission rates and disease control in adult patients. - Non‑Hodgkin lymphoma (NHL): induces tumor regression and prolongs progression‑free survival in eligible patients. - Mantle cell lymphoma (MCL): provides therapeutic benefit in patients with relapsed or refractory disease.

Adverse reactions may occur with Bendamustine therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Fatigue: generalized tiredness. - Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring prompt treatment. - Pulmonary toxicity: interstitial pneumonitis or respiratory distress. - Secondary malignancies: emergence of new cancers after therapy.

When using Bendamustine, careful monitoring and patient assessment are essential.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess infection risk: watch for fever or signs of infection. - Evaluate liver function: test hepatic enzymes before and during therapy. - Adjust dose in renal impairment: consider reduced dosing for decreased clearance. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine may interact with other medicines; clinical judgement is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Live vaccines: risk of infection due to immunosuppression. - Concurrent myelosuppressive agents: additive bone‑marrow toxicity. - Known hypersensitivity to nitrogen mustard compounds.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase bleeding risk. - Anticoagulants: monitor coagulation parameters. - CYP2C9 substrates: potential altered plasma levels. - Diuretics: watch for electrolyte disturbances.